Literature DB >> 3033388

Reversing glomerular hypertension stabilizes established glomerular injury.

T W Meyer, S Anderson, H G Rennke, B M Brenner.   

Abstract

Munich-Wistar rats were studied 18 weeks following 5/6 renal ablation. In untreated group 1 rats maintained on standard chow containing 24% protein, sustained systemic and glomerular hypertension were associated with increasing proteinuria and widespread glomerular injury. In group 2, early treatment with the converting enzyme inhibitor enalapril prevented systemic and glomerular hypertension, and largely limited proteinuria and glomerular injury. Groups 3 and 4 received no therapy during the first eight weeks, during which they developed systemic hypertension and levels of proteinuria previously shown to be associated with significant glomerular sclerosis at this time point. Enalapril therapy begun at eight weeks in group 3 rats reversed systemic and glomerular hypertension, prevented a further rise in proteinuria, and limited glomerular lesions at 18 weeks relative to group 1. Reduction of dietary protein content to 12% at eight weeks in group 4 rats controlled glomerular but not systemic hypertension to near-normal levels, stabilized proteinuria values, and also limited glomerular lesions at 18 weeks compared to group 1. These studies support the view that glomerular hypertension is an essential hemodynamic derangement responsible for progressive glomerular injury. Furthermore, reduction of capillary pressure can arrest the progression of remnant glomerular injury even when therapy is delayed until glomerular injury is established.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3033388     DOI: 10.1038/ki.1987.62

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  42 in total

Review 1.  Aldosterone as a determinant of cardiovascular and renal dysfunction.

Authors:  M Epstein
Journal:  J R Soc Med       Date:  2001-08       Impact factor: 5.344

Review 2.  Renal autoregulation in health and disease.

Authors:  Mattias Carlström; Christopher S Wilcox; William J Arendshorst
Journal:  Physiol Rev       Date:  2015-04       Impact factor: 37.312

3.  A rare case of milky urine.

Authors:  Hannes Neuwirt; Philipp Eller; Martin Tiefenthaler; Gert Mayer; Alexander R Rosenkranz
Journal:  Wien Klin Wochenschr       Date:  2010-09-30       Impact factor: 1.704

4.  Effects of enalapril on renal parameters in patients with primary glomerulopathies associated with chronic renal failure.

Authors:  L F Ferder; F Inserra; H Daccordi; L Romano; A Fernández; J Tessler
Journal:  Drugs       Date:  1990       Impact factor: 9.546

Review 5.  Benazepril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and congestive heart failure.

Authors:  J A Balfour; K L Goa
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

6.  Management of congenital nephrotic syndrome.

Authors:  Larisa Kovacevic; Christopher J D Reid; Susan P A Rigden
Journal:  Pediatr Nephrol       Date:  2003-04-08       Impact factor: 3.714

Review 7.  A potential role for mechanical forces in the detachment of podocytes and the progression of CKD.

Authors:  Wilhelm Kriz; Kevin V Lemley
Journal:  J Am Soc Nephrol       Date:  2014-07-24       Impact factor: 10.121

8.  Impact of initial treatment on renal function in newly-diagnosed type 2 (non-insulin-dependent) diabetes mellitus.

Authors:  J P Vora; J Dolben; J D Williams; J R Peters; D R Owens
Journal:  Diabetologia       Date:  1993-08       Impact factor: 10.122

9.  Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass.

Authors:  R A Lafayette; G Mayer; S K Park; T W Meyer
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

Review 10.  Angiotensin converting enzyme (ACE) inhibitors and renal function. A review of the current status.

Authors:  A L Kamper
Journal:  Drug Saf       Date:  1991 Sep-Oct       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.